VIP (Vasoactive Intestinal Peptide): The Complete 2026 Guide to CIRS, Mold Illness, and Pulmonary Therapy

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide that has quietly emerged as one of the most clinically significant compounds in integrative and functional medicine. While peptides like BPC-157 and semaglutide dominate the conversation, VIP is gaining serious attention — particularly for its role in treating Chronic Inflammatory Response Syndrome (CIRS), pulmonary conditions, and neurodegenerative disorders. This guide covers everything you need to know about VIP: what it is, how it works, who it's for, and what the clinical evidence shows.

What Is VIP (Vasoactive Intestinal Peptide)?

VIP belongs to the glucagon/secretin superfamily of peptides — the same family that includes GLP-1, GIP, glucagon, and secretin. It is produced endogenously throughout the body, with the highest concentrations in:

• The hypothalamus and cerebral cortex
• The enteric nervous system (gut)
• VIPergic nerve fibers innervating the thymus, spleen, and lymph nodes
• Bronchial smooth muscle and pulmonary vasculature
• CD4+ and CD8+ T lymphocytes (which produce VIP directly)

Its most critical structural feature is an alpha-helix spanning residues 5–24, with hydrophobic C-terminal residues that drive receptor binding. Despite its biological importance, endogenous VIP has an extraordinarily short plasma half-life of just 1.5–2.5 minutes — a pharmacological challenge that shapes every clinical protocol.

Mechanism of Action: VPAC1, VPAC2, and the cAMP Cascade

VIP signals through two primary G protein-coupled receptors: VPAC1 and VPAC2.

VPAC1 is expressed in the lung, liver, intestine, T lymphocytes, and dendritic cells. It is the dominant receptor mediating VIP's anti-inflammatory and immune-modulating effects. VPAC2 is found in smooth muscle, the pancreas, the hypothalamus, and critically — in the suprachiasmatic nucleus (SCN), the brain's master circadian clock.

Both receptors activate the same primary signaling cascade:

1. VIP binds VPAC1/VPAC2 → activates Gs protein
2. Gαs activates adenylyl cyclase
3. Adenylyl cyclase converts ATP to cyclic AMP (cAMP)
4. Elevated cAMP activates Protein Kinase A (PKA)
5. PKA phosphorylates downstream targets → CREB transcription factor → gene expression changes

This cascade produces a powerful anti-inflammatory profile: suppression of TNF-α, IFN-γ, IL-6, and IL-12; inhibition of NF-κB; and upregulation of IL-10, IL-1Ra, and regulatory T cells (Tregs). Simultaneously, VIP promotes VEGF production and stimulates the hypothalamic-pituitary axis to produce MSH (melanocyte-stimulating hormone).

Key Therapeutic Applications

1. CIRS and Mold Illness (Shoemaker Protocol)

This is where VIP has its most established clinical use. Dr. Ritchie Shoemaker, MD, pioneered the use of intranasal VIP as Step 12 — the final step — in his multi-step CIRS (Chronic Inflammatory Response Syndrome) Protocol.

CIRS is a multi-system illness triggered by biotoxin exposure from water-damaged buildings, Lyme disease, cyanobacteria, and other sources. In CIRS patients, endogenous VIP levels are characteristically depressed, contributing to a cascade of dysregulated inflammatory markers.

Published clinical findings:

• A 2013 study by Shoemaker showed that VIP administered intranasally (up to 600 mcg/day) safely normalized TGF-β1, MMP-9, C4a, and VEGF in CIRS patients
• A 2017 study using NeuroQuant MRI volumetric analysis demonstrated that VIP treatment (>12 weeks, >6 doses/day) restored grey matter volume in multiple brain nuclei — the first documented neurological tissue restoration via peptide therapy
• Over 300 physicians have prescribed intranasal VIP for CIRS; more than 90% reported reduced symptoms and normalized biomarkers

Critical protocol note: VIP must not be started until all prior Shoemaker protocol steps are completed. Using VIP with ongoing biotoxin exposure or active MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) can worsen symptoms significantly.

2. Pulmonary Arterial Hypertension (PAH)

VIP is a potent pulmonary vasodilator. Patients with PAH have significantly reduced circulating VIP levels, and lung tissue from PAH patients shows reduced VIP expression — suggesting VIP deficiency contributes to the disease.

Aviptadil (synthetic VIP) received FDA Orphan Drug Designation for PAH in 2005. Phase I/II inhaled aviptadil trials in 20 PAH patients showed temporary but significant reductions in mean pulmonary artery pressure, expanded cardiac output, and improved mixed venous oxygen saturation — with no adverse effects.

3. COVID-19 ARDS (Aviptadil/ZYESAMI)

VIP receptors (VPAC1/VPAC2) are highly expressed on alveolar type II pneumocytes — the cells destroyed in COVID-19 ARDS. Aviptadil (branded ZYESAMI) underwent Phase 2b/3 trials for critical COVID-19 with respiratory failure.

60-day trial results:

• 84% survival in HFNC (high-flow nasal cannula) patients receiving ZYESAMI vs. 60% survival in placebo
• 10-day reduction in median time to recovery
• No serious drug-related adverse events in the treatment arm
• Met the primary endpoint of recovery from respiratory failure at Day 28

ZYESAMI received FDA Fast Track designation — the only pulmonary therapeutic for COVID-19 to enter both Phase II and III trials simultaneously.

4. Asthma and Respiratory Inflammation

VIP-containing nerve fibers are densely distributed in bronchial smooth muscle. VIP acts as an endogenous bronchodilator and anti-inflammatory agent. Key evidence:

• A VPAC2-selective agonist (Ro25-1553) produced rapid-onset, significant FEV1 improvement in 24 moderate asthma patients without adverse effects
• Nebulized VIP in 20 sarcoidosis patients (4-week trial) was safe, well-tolerated, and significantly reduced TNF-α production — published in the American Journal of Respiratory and Critical Care Medicine

5. Inflammatory Bowel Disease (IBD)

VIP is naturally abundant in the enteric nervous system and plays a homeostatic role in intestinal immune balance. In ulcerative colitis, epithelial VIP expression is downregulated in inflamed colon tissue. Research shows VIP stimulates IL-10 in regulatory B cells (Bregs), which is deficient in UC.

Promising nanomedicine delivery approaches using VIP-SSM (sterically stabilized micelles) have shown significant benefit in preclinical IBD models — protecting VIP from rapid degradation and enabling targeted delivery to inflamed intestinal tissue. Clinical trials are ongoing.

6. Neurological and Neuroprotective Effects

VIP's role in the SCN makes it the only peptide directly regulating the mammalian circadian clock. Beyond circadian biology, VIP:

• Induces nerve growth factor (NGF) secretion from brain mast cells
• Stimulates activity-dependent neuroprotective protein (ADNP) — mutations in ADNP are the most common single-gene cause of autism spectrum disorder
• Has neuroprotective effects in cerebral ischemia models
• Shows altered expression in Alzheimer's, Parkinson's, and ALS patient samples
• Correlates with hippocampal and amygdala volume and emotional regulation (2021 Scientific Reports)

Dosing Protocols

Intranasal (CIRS / Shoemaker Protocol)

Subcutaneous Injectable (Titration Protocol)

Given VIP's ~2-minute plasma half-life, subcutaneous doses above 300 mcg per administration offer diminishing returns and increased vasodilatory side effects.

Side Effects and Safety

Common (mild, typically transient):

• Facial flushing and warmth (vasodilation)
• Mild hypotension / lightheadedness
• Headache at treatment initiation
• Nausea with rapid dose escalation
• Nasal irritation (intranasal route)

Significant considerations:

• Hypotension: The most clinically significant risk. Blood pressure monitoring is essential when initiating systemic VIP
• Watery diarrhea syndrome: At high systemic doses, VIP can mimic VIPoma effects (secretory diarrhea, hypokalemia)

Absolute contraindications:

• Baseline systolic BP below 100 mmHg
• Active malignancy — particularly VPAC receptor-positive tumors (breast, prostate, small cell lung cancer)
• Anticoagulation therapy or platelet count below 100,000/μL
• POTS or autonomic failure
• Known VIPoma or secretory diarrhea syndrome

Legal Status and Compounding Pharmacy Availability

VIP occupies a gray regulatory area in the United States. It has been available through licensed 503A compounding pharmacies with a valid physician prescription — primarily as intranasal nasal spray.

The FDA's Pharmacy Compounding Advisory Committee reviewed VIP in 2016 and found insufficient evidence for Category 1 status. Advocacy campaigns led by Dr. Shoemaker and ISEAI (International Society for Environmentally Acquired Illness) have pushed back. As of January 7, 2025, the FDA issued interim guidance allowing continued compounding while the final determination is pending.

Multiple compounding pharmacies continue to offer VIP nasal spray by prescription (2025–2026), including Strive Pharmacy, Wells Pharmacy Network, Restorative Compounding Pharmacy, PD Labs, and HydraMed. No FDA-approved VIP formulation exists for general prescription use in the U.S.

VIP vs. Other Anti-Inflammatory Peptides: Key Differences

How does VIP compare to other peptides in the anti-inflammatory and healing category?

• vs. BPC-157: BPC-157 excels at localized tissue repair (GI, musculoskeletal); VIP operates systemically with far stronger evidence in human clinical trials and unique neurological/circadian effects
• vs. Thymosin Alpha-1: TA1 is primarily immunostimulatory (Th1) and approved in 35+ countries for viral infections and cancer adjuvant therapy; VIP is anti-inflammatory/immunomodulatory (Treg/Th2) with a unique niche in CIRS and respiratory disease
• vs. TB-500: TB-500 targets structural tissue repair (actin regulation, anti-fibrotic); VIP targets the immune-nervous system interface with circadian, neurological, and vascular effects not shared by TB-500

VIP's unique advantages include being the only peptide with Phase 2b/3 human trial data for life-threatening respiratory failure, the only peptide with MRI-confirmed neurological tissue restoration data, and the only endogenous regulator of the circadian master clock.

The Bottom Line

Vasoactive Intestinal Peptide is one of the most biologically versatile peptides in the human body and one of the most underrecognized in the clinical peptide landscape. The evidence base — particularly for CIRS and pulmonary applications — is more robust than most people realize. Its constraints (short half-life, hypotension risk, regulatory uncertainty, strict prerequisite steps in CIRS) are real but manageable with appropriate clinical oversight.

If you're dealing with treatment-resistant CIRS, mold illness, pulmonary hypertension, or inflammatory bowel conditions, VIP may warrant a serious conversation with an experienced physician who understands the full Shoemaker protocol or relevant specialty context. As compounding access continues to evolve, VIP's clinical role is likely to grow — particularly if the ongoing FDA review preserves compounding access and Aviptadil eventually reaches formal approval for respiratory indications.

This article is for educational purposes only. VIP is a prescription compound and must be used under physician supervision. The FDA has not approved any VIP formulation for general prescription use in the United States.